Management of Erythromelalgia in Adult Patients

Conclusions

• Erythromelalgia in adults is usually a chronic, incurable pain syndrome, so treatment should focus on realistic expectations and restoring function rather than promising cure.
• Most patients can achieve meaningful improvement with a stepwise approach that starts with nonpharmacologic measures and topical therapies before moving to systemic drugs or procedures.
• Cooling strategies should be used cautiously, because brief cooling may help symptoms but prolonged ice-water immersion can cause injury such as trench foot.
• Topical amitriptyline-ketamine and lidocaine are among the most useful first-line pain treatments, with retrospective data suggesting improvement in a substantial proportion of patients.
• Topical midodrine can be helpful, especially for erythema, and appears well tolerated in small cohorts.
• Certain common medications can worsen erythromelalgia, especially calcium channel blockers like amlodipine and stimulant/amphetamine medications, so stopping culprit drugs may improve symptoms.
• Aspirin is worth a trial for at least four weeks, particularly in patients with myeloproliferative disease, but may also help some others.
• A subset of patients with acute or subacute disease, especially after trauma, surgery, or infection, may respond dramatically to high-dose corticosteroids.
• Neuropathic pain agents such as gabapentin, pregabalin, venlafaxine, and sometimes mexiletine or carbamazepine can be useful when topical and simpler systemic options fail.
• Clonidine patches are a reasonable adjunct because they may reduce pain and inflammation and are generally well tolerated when titrated carefully.
• Newer options such as suzetrigine and fezolinetant may have a role in selected patients, but they remain emerging or repurposed therapies rather than established standards.
• For refractory disease, procedural approaches and especially scrambler therapy may offer benefit when many medications and even spinal cord stimulation have failed.